Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510378 | 1.00 | CYP1A2 (0.35) | CYP1A2TSHRSLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30510422 | 0.95 | NPY5R (0.39) | NPY5R | |
| SCHEMBL25179536 | 0.95 | NPY5R (0.39) | NPY5R | |
| SCHEMBL25173094 | 0.95 | NPY5R (0.36) | CYP1A2TSHRSLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30510390 | 0.95 | NPY5R (0.36) | CYP1A2TSHRSLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5409646 | 0.94 | NPY5R (0.40) | NPY5R | |
| SCHEMBL30510220 | 0.94 | NPY5R (0.40) | NPY5R | |
| SCHEMBL7718775 | 0.86 | CHRNB2 (0.42) | SLC6A4SLC6A3CYP2D6SLC6A2CHRM3 | |
| SCHEMBL25177898 | 0.85 | CYP1A2 (0.37) | CYP1A2TSHRMAPTKMT2AGPR3 | |
| SCHEMBL8893033 | 0.85 | CYP1A2 (0.37) | CYP1A2TSHRMAPTKMT2AGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CYP1A2 4845/4885TSHR 3295/4885SLC6A4 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.